The American Association for Thoracic Surgery has announced a new partnership with the Cardiothoracic Surgical Trials Network. The groups plan on working together to address current challenges in cardiothoracic surgery research.
Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.
Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new gene therapies for the treatment of cardiovascular disease. Tenaya will receive an upfront payment of $10 million, but stands to earn much more.
Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
![The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.](/sites/default/files/styles/240x220/public/2024-12/screenshot_2024-12-02_at_11.07.21_am.png.webp?itok=d6Myns-z)
